Engineered Multifunctional Drug-Loaded Dendrimer Nanoparticles for Glaucoma: Triple Mechanism via Antioxidant Activity, Iron Chelation, and Enhanced Ocular Transport
Biomacromolecules · 2025
DOI: 10.1021/acs.biomac.5c01704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomacromolecules, 2025. Verfasst von Burhan Ates und 6 weiteren Autor:innen. Beteiligte Einrichtung: Linda and Bipin Doshi Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, Rolla, Missouri 65409, Unite…. Hauptthemen laut MEDLINE: Dendrimers, Glaucoma, Antioxidants, Nanoparticles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
In this study, we developed multifunctional nanoparticles based on polyamidoamine (PAMAM) dendrimers functionalized with caffeic acid (CA) and poly(ethylene glycol) maleimide (PEGM) for the topical delivery of hydrophobic antiglaucoma drugs brimonidine (BM) and betaxolol (BX). The PAMAM-CA and PAMAM-CA-PEGM conjugates exhibited antioxidant and iron-chelating activities in a dose-dependent manner. BM- and BX-loaded dendrimer nanoparticles produced using a multi-inlet vortex mixer showed uniform spherical morphology (∼80 nm by TEM) and hydrated sizes of ∼135–144 nm by DLS. Both nanoformulations demonstrated high cytocompatibility with human corneal epithelial cells and were nonirritant in the HET-CAM assay, with PEGM further improving cytocompatibility. Drug release was sustained for 8 h. Ex vivo corneal permeation studies revealed significantly enhanced drug transport, with PAMAM-CA and PAMAM-CA-PEGM nanoparticles achieving approximately 2- and 3-fold higher permeation, respectively, compared to commercial formulations. Conjugation of CA within our formulations effectively promoted the removal of ferric ions from the surrounding environment. Both PAMAM-CA and PAMAM-CA-PEGM nanoparticles exhibited concentration-dependent antioxidant activity comparable to that of CA. These findings suggest the potential of this multifunctional dendrimer-based nanoparticle system as an innovative strategy for glaucoma medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Linda and Bipin Doshi Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, Rolla, Missouri 65409, United States.
- Department of Chemistry, Faculty of Arts and Sciences, Inonu University, Malatya 44280, Turkey.
- Joint Department of Biomedical Engineering, Marquette University and Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States.
ORCID-Profile: Burhan Ates, Hu Yang
Förderung
- NEI NIH HHS
- National Institutes of Health
Zitieren
APA
Ates, B., Trital, A., Mani, V. J., Xu, L., Kenlee, J., Ercal, N., & Yang, H. (2025). Engineered Multifunctional Drug-Loaded Dendrimer Nanoparticles for Glaucoma: Triple Mechanism via Antioxidant Activity, Iron Chelation, and Enhanced Ocular Transport. Biomacromolecules. https://doi.org/10.1021/acs.biomac.5c01704
Vancouver
Ates B, Trital A, Mani VJ, Xu L, Kenlee J, Ercal N, et al. Engineered Multifunctional Drug-Loaded Dendrimer Nanoparticles for Glaucoma: Triple Mechanism via Antioxidant Activity, Iron Chelation, and Enhanced Ocular Transport. Biomacromolecules. 2025. doi:10.1021/acs.biomac.5c01704
BibTeX
@article{Ates2025,
author = {Ates, Burhan and Trital, Ashish and Mani, Vimalin Jeyalatha and Xu, Lei and Kenlee, Jonathan and Ercal, Nuran and Yang, Hu},
title = {Engineered Multifunctional Drug-Loaded Dendrimer Nanoparticles for Glaucoma: Triple Mechanism via Antioxidant Activity, Iron Chelation, and Enhanced Ocular Transport},
journal = {Biomacromolecules},
year = {2025},
doi = {10.1021/acs.biomac.5c01704}
}
EUVIMED